Search the Newsreel

CVRx (NASDAQ:CVRX) COO Brent Binkowski Buys 26,223 Shares of Stock

CVRx COO Brent Binkowski recently purchased 26,223 shares of CVRx stock for $2.91 per share, increasing his total holdings to 56,514 shares. This purchase followed a sale of 1,309 shares the previous day. Despite the insider buying and a 7.7% stock increase, CVRx continues …

Insider Purchase: CHIEF OPERATING OFFICER of $CVRX Buys 26,223 Shares

Brent Binkowski, the Chief Operating Officer of CVRX, purchased 26,223 shares of the company stock for an estimated $76,432, increasing his holdings by 86.6%. This transaction was part of 9 insider trades in the past six months, with 3 purchases and 6 sales. The …

CVRx (CVRX) COO Brent Binkowski purchases 26,223 shares in open-market buy

Brent Binkowski, Chief Operating Officer of CVRx, Inc. (CVRX), purchased 26,223 shares of the company's common stock on August 13, 2026. The open-market transactions occurred at a weighted average price of $2.9147 per share, with individual trade prices ranging from $2.87 to $2.96. Following …

Block & Leviton investigates CVRx for possible securities law violations after revenue guidance cut.

Block & Leviton is investigating CVRx, Inc. for potential securities law violations after the company reduced its full-year revenue guidance. The lowered guidance is attributed to sales execution issues, high employee turnover, and reimbursement challenges. Additionally, CVRx revealed a Department of Justice inquiry into …

CVRx Eyes Barostim Growth as Coverage Gains and BENEFIT-HF Trial Launches

CVRx is focusing on expanding the adoption of its Barostim therapy for heart failure, targeting the "forgotten middle" of patients with NYHA Class II/III heart failure. The company is refining its commercial strategy, improving reimbursement particularly with Medicare, and has launched the large-scale BENEFIT-HF …

CCORF Maintains CVRx Inc(CVRX.US) With Buy Rating, Cuts Target Price to $5

CCORF has reiterated its Buy rating for CVRx Inc (CVRX.US) but has revised its target price downwards to $5. This adjustment indicates a continued positive outlook on the company's stock, despite a reduction in the expected price target.

CVRx chief revenue officer exits amid slowing sales and execution concerns

CVRx Inc. has announced the departure of its chief revenue officer following a reduction in its full-year revenue guidance. The company attributes the lowered outlook to employee turnover and productivity issues, which have impacted sales of its primary product, Barostim, a device for heart …

CVRx, Inc. $CVRX Shares Acquired by Royal Bank of Canada

Royal Bank of Canada significantly increased its stake in CVRx, Inc. (NASDAQ:CVRX) during the first quarter, acquiring over 696,000 additional shares to own 2.66% of the company. Despite this, analyst sentiment has weakened, with several downgrades to "Hold" or "Neutral" and an average price …

CVRx, Inc. Investors With Losses Should Contact Block & Leviton About Securities Fraud Investigation

Block & Leviton is investigating CVRx, Inc. (Nasdaq:CVRX) for potential securities law violations after the company cut its full-year revenue guidance, citing sales-force issues, elevated turnover, and a prolonged reimbursement challenge. The investigation also concerns a civil investigative demand from the Department of Justice …

CVRx, Inc. (CVRX) Presents at Canaccord Genuity's 46th Annual Growth Conference - Slideshow

CVRX: Execution improvements and payer wins position the therapy for broader adoption and growth

CVRx, Inc. (CVRX) is addressing execution challenges in sales onboarding for its novel heart failure device, which targets a large and underserved market. The company is poised for broader adoption and growth due to strong Medicare coverage and anticipated improved payer coverage following Humana's …

CVRx Inc (CVRX) Stock News Today

CVRx to replace CRO after cutting guidance and DOJ civil inquiry

CVRx announced it has let go of its Chief Revenue Officer Robert John and appointed Paul Verrastro as interim head of sales, following a disappointing earnings report and a disclosed Department of Justice civil investigation into its sales and marketing practices. The company also …

CVRx (CVRX) ousts CRO, installs interim sales head as outlook shifts

CVRx, Inc. announced the departure of Chief Revenue Officer Robert John and the appointment of Paul Verrastro as Interim Head of Sales, effective immediately. This leadership change is attributed to a revised commercial outlook and the need to improve commercial execution. Verrastro, with over …

CV's Robert John departs as Chief Revenue Officer

Robert John, Chief Revenue Officer of CVRX, terminated his employment with the company effective August 10, 2026. He is entitled to severance pay and benefits as per his employment agreement. The reason for his departure and information regarding his replacement were not disclosed.

Securities Fraud Investigation Into CVRx, Inc. (CVRX) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Glancy Prongay Wolke & Rotter LLP has launched a securities fraud investigation into CVRx, Inc. (CVRX) after the company disclosed a civil investigative demand from the U.S. Department of Justice concerning sales and marketing practices, including potential false claims and kickbacks. This news, coupled …

(CVRX) Price Dynamics and Execution-Aware Positioning

This article provides an AI-driven analysis of Cvrx Inc. (NASDAQ: CVRX), highlighting weak sentiment across all horizons and a short bias. It details institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels. …

CVRx, Inc. (NASDAQ:CVRX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

CVRx, Inc. (NASDAQ:CVRX) experienced a significant share price drop of 54% following its second-quarter results, which met revenue expectations but reported wider losses than anticipated. Analysts have subsequently lowered their revenue forecasts for 2026 and increased their per-share loss expectations, leading to a 47% …

CVRx Falls To US$2.39, But Insiders Sold At Lower Price

The article discusses CVRx's recent stock price decline to US$2.39, highlighting that while the stock has fallen, insiders had sold shares at an even lower price of US$2.05 in the past year. This insider selling activity, despite the lower price point, raises questions about …

CVRx Inc (CVRX) Earnings Forecast: Future EPS & Revenue Growth Estimates

CVRx, Inc. (NASDAQ:CVRX) Given Consensus Recommendation of "Hold" by Brokerages

CVRx, Inc. (NASDAQ:CVRX) has received a consensus "Hold" recommendation from six brokerages, with an average 12-month price target of $6.90. The company's stock recently fell significantly to $2.72 after reporting a $0.53-per-share quarterly loss and negative net margin, despite beating revenue expectations. Analysts have …

CVRx (NASDAQ:CVRX) Rating Lowered to Sell at Wall Street Zen

CVRx (NASDAQ:CVRX) has had its rating lowered to "sell" by Wall Street Zen, with several other analysts also reducing their ratings due to concerns about profitability and execution. The company reported a quarterly loss and negative margins, leading to a cut in revenue guidance …

IMA,CVRX Volatility & Greeks

This article provides detailed financial data and performance metrics for two companies, ImageneBio Inc (IMA) and CVRx Inc (CVRX). It includes information on their stock performance, market capitalization, income, sales, volatility, and various financial ratios, offering a snapshot of their current market standing.

CVRx, Inc. Stock 12‑Month Price Target Cut to $8, Implies 35% Upside

CVRx, Inc.'s stock 12-month price target has been lowered from $11.17 to $8, according to estimates from 5 analysts, with a range of $4 to $14 per share. This new target suggests a potential upside of approximately 35% from the August 6 closing price. …

Key facts: CVRx, Inc. Q2 revenue +16%; Humana adds Barostim

CVRx, Inc. (CVRX) reported Q2 revenue of $15.7 million, a 16% increase year-over-year, with U.S. sales up 21% to $14.8 million. The company achieved an 87% gross profit margin, resulting in a net loss of $14.0 million, and holds $64.6 million in cash. Additionally, …

Law firm probes CVRx over possible securities l...

A law firm is investigating CVRx, Inc. and its executives for potential securities law violations after the company cut its 2026 revenue guidance and disclosed a Department of Justice inquiry. The revenue guidance reduction was attributed to challenges such as high employee turnover, slow …

Piper Sandler cuts CVRx stock rating on sales, reimbursement issues

Piper Sandler downgraded CVRx Inc (NASDAQ:CVRX) to Neutral from Overweight and lowered its price target to $4.00 from $12.00, citing sales force issues and challenges in obtaining consistent reimbursement from its largest payer. While CVRx's second-quarter revenue surpassed estimates, the company reduced its full-year …

CVRx (CVRX) Stock Reels From Guidance Cut And Cash Burn Fears

CVRx (CVRX) stock dropped almost 60% after cutting its 2026 revenue guidance to US$58m-US$60m and providing softer Q3 guidance. Despite strong Q2 revenue of US$15.7m and high gross margins of 87%, the company reported a US$14.0m net loss and continues to burn cash, raising …

CVRx Shares Slide on Sales View Cut

CVRx shares dropped after the company announced a cut in its sales guidance. This adjustment in financial outlook indicates potential challenges or revised expectations for the company's performance.

CVRx, Inc. (CVRX) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel Following Revenue Guidance Cut and Sales-Execution Disclosures

Johnson Fistel, PLLP is investigating CVRx, Inc. (CVRX) after the company significantly lowered its full-year revenue guidance to $58 million–$60 million, down from $63 million–$67 million. This reduction is attributed to challenges with sales-force execution, high turnover, and difficulties with onboarding and training new …

CVRx (NASDAQ:CVRX) Announces Quarterly Earnings Results

CVRx Q2 Earnings Call Highlights

CVRx Inc (CVRX) reported Q2 2026 revenue of $15.7 million, up 16% year-over-year, with an 87% gross margin. However, the company lowered its full-year 2026 revenue guidance due to sales execution issues, including high sales force turnover and challenges with a major Medicare Advantage …

[10-Q] CVRx, Inc. Quarterly Earnings Report

CVRx, Inc. filed its unaudited interim quarterly report (Form 10-Q) for the period ended June 30, 2026. The report details the company's financial position, including $60.0 million in debt, $64.6 million in cash, and $49.2 million in remaining ATM equity issuance capacity. The company …